## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing of Claims**

Claims 1 - 33. Cancelled.

Claim 34. (Currently Amended): A method of modulating a biological activity comprising administering a neuroactive peptide comprising to a mammal a neuroactive peptide in an amount effective for modulating neuronal activity that mediates said biological activity, wherein said neuroactive peptide comprises the amino acid sequence:

Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe, (SEQ ID NO:1)

to a mammal in an amount effective to facilitate said biological activity, wherein said biological activity is selected from the group consisting of learning and short-term memory retrieval and wherein said biological activity is facilitating learning.

Claim 35. Cancelled.

Claim 36. (Currently Amended): The method of claim 34, wherein in which the mammal is human.

Claim 31. (Previously Presented): The method of claim 34, wherein the peptide is administered as a composition further comprising a pharmaceutically acceptable carrier.

Claim 38. Cancelled.

Claim 39. (Currently Amended): The method of claim 34, wherein said peptide is administered in an amount effective for treating a disease or condition associated with an abnormality in said biological activity, said abnormality being mediated by abnormality of said neuronal activity.

Claim 10. (Previously Presented): The method of claim 34, wherein the peptide is administered intracerebrally.

Claim 41. Cancelled.

Claim 42. (Previously Presented): The method of claim 39, wherein the peptide is administered intracerebrally.

Claim 43. (Currently Amended): The method according to claim 39, wherein <u>said</u> peptide is administered in an amount effective for treating amnesia or a disorder involving disease or condition is selected from the group consisting of dementia; Alzheimer's disease; neuro degenerative disorders involving one or more of cholinergic pathways, motor pathways[[,]] or sensory pathways; motor neuron disease; sensory peripheral neuropathies; motor peripheral neuropathies; brain injury; and spinal cord injury resulting from one or more of trauma, hypoxia, and vascular disease.

Claim 4. (Previously Presented): A method according to claim 24, wherein said neuroactive peptide additionally has vasoactive effects, dilates cerebral arteries, or increases renal blood flow.

Claim 15. (Previously Presented): A method according to claim 24, wherein said neuroactive peptide comprises one or more D-amino acids.

Claim 16. (Previously Presented): A method according to claim 29, wherein said neuroactive peptide comprises one or more D-amino acids.

Claims 47 - 48. Cancelled.